$8.70
▼ -1.6% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Overview
52-week range
$6.72
$21
14% of range
Avg surprise (last 3)
-0.3%
Avg reaction (last 2)
-6.1%
50% positive
Latest IV / EM
151%
EM ±34.5% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-1.23 | $-1.26 | +2.4% | +11.5% | +3.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.90 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-1.44 | $-1.55 | +7.1% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.39 | $-1.26 | -10.3% | — | -15.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.90 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.83 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.27 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.05 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$1.30 | -$1.44 | +9.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | — | $-24M | $-19M | $-20M | — | $-16M | $-11M |
| Net income | $-23M | — | $-23M | $-18M | $-17M | — | $-14M | $-10M |
| EPS (diluted) | $-1.23 | — | $-1.90 | $-1.44 | $-1.39 | — | $-1.15 | $-0.90 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $26M | $28M | $27M | $20M | $19M | $17M | $19M | $24M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $144M | $167M | $108M | $123M | $137M | $153M | $161M | $148M |
| Total assets | $144M | $168M | $110M | $125M | $140M | $156M | $164M | $152M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $18M | $21M | $17M | $14M | $13M | $13M | $14M | $26M |
| Total equity | $126M | $148M | $92M | $111M | $127M | $142M | $150M | $126M |